| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neoplasms, Experimental | 35 | 2021 | 269 | 6.520 |
Why?
|
| Antigens, Neoplasm | 40 | 2021 | 325 | 4.630 |
Why?
|
| Neoplasms | 32 | 2021 | 2898 | 2.920 |
Why?
|
| Immunotherapy, Adoptive | 8 | 2023 | 170 | 2.390 |
Why?
|
| T-Lymphocytes, Cytotoxic | 23 | 2012 | 315 | 2.330 |
Why?
|
| T-Lymphocytes | 25 | 2023 | 1195 | 2.280 |
Why?
|
| Stromal Cells | 13 | 2017 | 143 | 2.120 |
Why?
|
| Receptors, Antigen, T-Cell | 13 | 2019 | 372 | 2.090 |
Why?
|
| CD4-Positive T-Lymphocytes | 15 | 2017 | 425 | 2.060 |
Why?
|
| CD8-Positive T-Lymphocytes | 15 | 2019 | 559 | 1.720 |
Why?
|
| Tumor Escape | 7 | 2017 | 49 | 1.600 |
Why?
|
| Mice | 92 | 2023 | 11352 | 1.530 |
Why?
|
| Animals | 108 | 2023 | 26582 | 1.350 |
Why?
|
| Cancer Vaccines | 9 | 2014 | 156 | 1.240 |
Why?
|
| Interferon-gamma | 9 | 2017 | 444 | 1.220 |
Why?
|
| Mice, Inbred C57BL | 34 | 2023 | 3092 | 1.180 |
Why?
|
| Neoplasms, Radiation-Induced | 12 | 2001 | 109 | 1.150 |
Why?
|
| Immunotherapy | 13 | 2021 | 629 | 1.140 |
Why?
|
| T-Lymphocyte Subsets | 6 | 2015 | 272 | 1.110 |
Why?
|
| Antigen Presentation | 9 | 2013 | 209 | 1.070 |
Why?
|
| Adoptive Transfer | 10 | 2019 | 168 | 1.030 |
Why?
|
| Mice, Inbred C3H | 25 | 2013 | 370 | 0.950 |
Why?
|
| Antigens | 5 | 2010 | 228 | 0.910 |
Why?
|
| Cell Line, Tumor | 21 | 2020 | 2426 | 0.910 |
Why?
|
| Mutation | 13 | 2021 | 3968 | 0.850 |
Why?
|
| Bystander Effect | 3 | 2015 | 12 | 0.850 |
Why?
|
| Point Mutation | 6 | 2015 | 246 | 0.790 |
Why?
|
| Mice, Knockout | 16 | 2020 | 1924 | 0.780 |
Why?
|
| Histocompatibility Antigens Class I | 7 | 2015 | 203 | 0.750 |
Why?
|
| Myeloid Cells | 2 | 2013 | 98 | 0.750 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 5 | 2013 | 123 | 0.710 |
Why?
|
| Neoplasm Transplantation | 18 | 2019 | 391 | 0.710 |
Why?
|
| Programmed Cell Death 1 Receptor | 3 | 2019 | 159 | 0.700 |
Why?
|
| Antibodies, Monoclonal | 8 | 2019 | 1376 | 0.690 |
Why?
|
| Friends | 1 | 2019 | 17 | 0.680 |
Why?
|
| Mice, Transgenic | 18 | 2015 | 1540 | 0.650 |
Why?
|
| Mice, Nude | 22 | 2020 | 790 | 0.630 |
Why?
|
| Interleukin-15 | 3 | 2013 | 72 | 0.620 |
Why?
|
| HLA-A2 Antigen | 4 | 2013 | 31 | 0.610 |
Why?
|
| Tumor Microenvironment | 5 | 2023 | 418 | 0.590 |
Why?
|
| Ovarian Neoplasms | 2 | 2023 | 744 | 0.570 |
Why?
|
| Cancer-Associated Fibroblasts | 1 | 2016 | 36 | 0.550 |
Why?
|
| Oncogene Proteins, Viral | 4 | 2020 | 34 | 0.540 |
Why?
|
| eIF-2 Kinase | 1 | 2015 | 46 | 0.540 |
Why?
|
| H-2 Antigens | 7 | 2005 | 58 | 0.530 |
Why?
|
| Tumor Cells, Cultured | 13 | 2020 | 1041 | 0.530 |
Why?
|
| Lymphocyte Activation | 10 | 2013 | 728 | 0.530 |
Why?
|
| Tumor Necrosis Factor-alpha | 8 | 2004 | 683 | 0.530 |
Why?
|
| Immunologic Memory | 3 | 2013 | 152 | 0.520 |
Why?
|
| B7-H1 Antigen | 1 | 2017 | 250 | 0.510 |
Why?
|
| Tamoxifen | 2 | 2006 | 168 | 0.480 |
Why?
|
| Recombinant Fusion Proteins | 4 | 2016 | 557 | 0.480 |
Why?
|
| Killer Cells, Natural | 4 | 2013 | 267 | 0.480 |
Why?
|
| Immunodominant Epitopes | 3 | 2019 | 19 | 0.470 |
Why?
|
| Immunization | 8 | 2013 | 158 | 0.470 |
Why?
|
| Flow Cytometry | 4 | 2012 | 679 | 0.470 |
Why?
|
| CTLA-4 Antigen | 1 | 2014 | 135 | 0.460 |
Why?
|
| HLA-D Antigens | 1 | 2013 | 20 | 0.460 |
Why?
|
| Cytotoxicity, Immunologic | 13 | 2016 | 213 | 0.450 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2017 | 592 | 0.450 |
Why?
|
| Fibroblasts | 3 | 2019 | 729 | 0.450 |
Why?
|
| Spleen | 3 | 2013 | 430 | 0.430 |
Why?
|
| Paracrine Communication | 1 | 2011 | 31 | 0.410 |
Why?
|
| Antigens, Tumor-Associated, Carbohydrate | 5 | 2020 | 11 | 0.410 |
Why?
|
| Epitopes, T-Lymphocyte | 4 | 2016 | 89 | 0.400 |
Why?
|
| Cross-Priming | 4 | 2015 | 48 | 0.400 |
Why?
|
| Glycoproteins | 2 | 2019 | 234 | 0.400 |
Why?
|
| Repressor Proteins | 3 | 2020 | 403 | 0.390 |
Why?
|
| Gelatinases | 1 | 2010 | 10 | 0.390 |
Why?
|
| Autoantigens | 2 | 2010 | 127 | 0.390 |
Why?
|
| Membrane Glycoproteins | 4 | 2019 | 428 | 0.390 |
Why?
|
| Macrophages | 1 | 2013 | 554 | 0.380 |
Why?
|
| Amino Acid Sequence | 10 | 2020 | 2062 | 0.370 |
Why?
|
| Serine Endopeptidases | 1 | 2010 | 145 | 0.370 |
Why?
|
| Fibrosarcoma | 5 | 2010 | 84 | 0.360 |
Why?
|
| Cytokines | 5 | 2023 | 776 | 0.360 |
Why?
|
| Peptide Fragments | 5 | 2013 | 460 | 0.360 |
Why?
|
| Ribosomes | 1 | 2010 | 111 | 0.360 |
Why?
|
| Immune Tolerance | 6 | 2010 | 337 | 0.350 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2013 | 1197 | 0.350 |
Why?
|
| Signal Transduction | 3 | 2019 | 3241 | 0.350 |
Why?
|
| Ultraviolet Rays | 9 | 2001 | 193 | 0.340 |
Why?
|
| Antibodies, Neoplasm | 4 | 2003 | 84 | 0.330 |
Why?
|
| Graft Rejection | 11 | 2007 | 1065 | 0.330 |
Why?
|
| Skin Neoplasms | 6 | 2012 | 546 | 0.330 |
Why?
|
| Tumor Necrosis Factors | 1 | 2008 | 14 | 0.330 |
Why?
|
| Humans | 45 | 2023 | 86643 | 0.320 |
Why?
|
| Autoimmunity | 3 | 2013 | 160 | 0.310 |
Why?
|
| Epitopes | 8 | 2020 | 255 | 0.310 |
Why?
|
| Histocompatibility Antigens Class II | 2 | 2017 | 158 | 0.310 |
Why?
|
| Viral Proteins | 2 | 2006 | 300 | 0.300 |
Why?
|
| Terminology as Topic | 2 | 2007 | 217 | 0.290 |
Why?
|
| Transfection | 8 | 2004 | 896 | 0.290 |
Why?
|
| Molecular Sequence Data | 12 | 2009 | 3030 | 0.290 |
Why?
|
| Papillomavirus E7 Proteins | 4 | 2020 | 31 | 0.280 |
Why?
|
| DNA, Neoplasm | 4 | 2012 | 265 | 0.280 |
Why?
|
| Recombinases | 1 | 2006 | 21 | 0.280 |
Why?
|
| Molecular Chaperones | 1 | 2006 | 111 | 0.280 |
Why?
|
| Green Fluorescent Proteins | 4 | 2016 | 305 | 0.280 |
Why?
|
| Gene Targeting | 1 | 2006 | 72 | 0.280 |
Why?
|
| Membrane Proteins | 2 | 2010 | 1196 | 0.280 |
Why?
|
| ras Proteins | 2 | 2004 | 128 | 0.270 |
Why?
|
| DNA-Binding Proteins | 3 | 2013 | 1208 | 0.270 |
Why?
|
| Histones | 1 | 2008 | 311 | 0.270 |
Why?
|
| CD4 Antigens | 2 | 2019 | 83 | 0.270 |
Why?
|
| Immunity, Cellular | 5 | 1995 | 177 | 0.270 |
Why?
|
| Genes, Reporter | 1 | 2006 | 268 | 0.270 |
Why?
|
| ErbB Receptors | 1 | 2008 | 485 | 0.270 |
Why?
|
| Genes, MHC Class I | 6 | 2012 | 48 | 0.270 |
Why?
|
| Antigens, Viral | 1 | 2005 | 143 | 0.260 |
Why?
|
| Cachexia | 3 | 1993 | 12 | 0.250 |
Why?
|
| Growth Inhibitors | 1 | 2004 | 41 | 0.240 |
Why?
|
| Tumor Burden | 2 | 2017 | 289 | 0.240 |
Why?
|
| Cell Line | 5 | 2019 | 2468 | 0.240 |
Why?
|
| Recombination, Genetic | 1 | 2006 | 439 | 0.240 |
Why?
|
| Melanoma, Experimental | 3 | 2013 | 103 | 0.230 |
Why?
|
| Glycosylation | 4 | 2019 | 129 | 0.230 |
Why?
|
| Disease Progression | 4 | 2011 | 1531 | 0.230 |
Why?
|
| Oligopeptides | 3 | 2013 | 179 | 0.230 |
Why?
|
| Carcinogens | 2 | 2020 | 108 | 0.220 |
Why?
|
| Immunologic Surveillance | 3 | 1991 | 14 | 0.220 |
Why?
|
| Phosphoproteins | 1 | 2004 | 254 | 0.220 |
Why?
|
| Sarcoma, Experimental | 4 | 2004 | 53 | 0.220 |
Why?
|
| Bone Marrow Cells | 2 | 2003 | 253 | 0.220 |
Why?
|
| Neoplasm Proteins | 3 | 1998 | 532 | 0.220 |
Why?
|
| Transforming Growth Factor beta | 3 | 2020 | 301 | 0.220 |
Why?
|
| Female | 33 | 2023 | 44532 | 0.220 |
Why?
|
| Receptors, Tumor Necrosis Factor | 3 | 2008 | 88 | 0.210 |
Why?
|
| B-Lymphocytes | 6 | 2004 | 724 | 0.210 |
Why?
|
| Dendritic Cells | 2 | 2013 | 425 | 0.210 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 2 | 2019 | 100 | 0.200 |
Why?
|
| Bone Marrow | 5 | 1995 | 435 | 0.200 |
Why?
|
| Mice, Inbred BALB C | 9 | 2007 | 1047 | 0.200 |
Why?
|
| Base Sequence | 8 | 2006 | 2330 | 0.200 |
Why?
|
| Trans-Activators | 1 | 2004 | 429 | 0.200 |
Why?
|
| Receptors, Chemokine | 2 | 2013 | 31 | 0.200 |
Why?
|
| CD11b Antigen | 2 | 2013 | 36 | 0.190 |
Why?
|
| Histocompatibility Antigens | 2 | 2019 | 35 | 0.190 |
Why?
|
| Disease Models, Animal | 4 | 2019 | 2232 | 0.190 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 22 | 1 | 2020 | 5 | 0.190 |
Why?
|
| Oncogene Protein p21(ras) | 1 | 2000 | 6 | 0.190 |
Why?
|
| Vaginal Neoplasms | 1 | 2020 | 83 | 0.190 |
Why?
|
| Necrosis | 3 | 2017 | 204 | 0.190 |
Why?
|
| Papilloma | 1 | 2000 | 22 | 0.190 |
Why?
|
| Adenoviridae | 2 | 2020 | 345 | 0.190 |
Why?
|
| CD3 Complex | 3 | 2019 | 135 | 0.190 |
Why?
|
| Oncolytic Virotherapy | 1 | 2020 | 41 | 0.190 |
Why?
|
| Glycine | 1 | 2000 | 92 | 0.180 |
Why?
|
| Recombinant Proteins | 4 | 2011 | 1014 | 0.180 |
Why?
|
| Arginine | 1 | 2000 | 136 | 0.180 |
Why?
|
| Bone Neoplasms | 2 | 2020 | 322 | 0.180 |
Why?
|
| Receptors, Interferon | 3 | 2017 | 31 | 0.180 |
Why?
|
| Estrogens | 1 | 2020 | 200 | 0.180 |
Why?
|
| Ribosomal Proteins | 2 | 2001 | 43 | 0.180 |
Why?
|
| Vaccination | 3 | 2004 | 254 | 0.180 |
Why?
|
| Cell Culture Techniques | 1 | 2020 | 188 | 0.170 |
Why?
|
| Cell Communication | 1 | 2020 | 194 | 0.170 |
Why?
|
| Inflammation | 1 | 2004 | 920 | 0.170 |
Why?
|
| Models, Biological | 3 | 2013 | 1749 | 0.170 |
Why?
|
| Polymerase Chain Reaction | 5 | 2012 | 927 | 0.170 |
Why?
|
| Leukocytes | 2 | 1996 | 202 | 0.170 |
Why?
|
| Granulocytes | 2 | 1995 | 37 | 0.160 |
Why?
|
| Gene Expression | 5 | 2012 | 1284 | 0.160 |
Why?
|
| Xenograft Model Antitumor Assays | 4 | 2023 | 458 | 0.160 |
Why?
|
| Genetic Vectors | 4 | 2020 | 439 | 0.160 |
Why?
|
| Immunotherapy, Active | 2 | 1998 | 15 | 0.160 |
Why?
|
| Mice, Inbred Strains | 6 | 2016 | 307 | 0.160 |
Why?
|
| Antigen-Presenting Cells | 2 | 2010 | 139 | 0.160 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2020 | 275 | 0.160 |
Why?
|
| Mouth Neoplasms | 1 | 2019 | 194 | 0.150 |
Why?
|
| RNA Nucleotidyltransferases | 1 | 1997 | 11 | 0.150 |
Why?
|
| Vascular Remodeling | 1 | 2017 | 21 | 0.150 |
Why?
|
| Peptides | 3 | 2012 | 639 | 0.150 |
Why?
|
| Endoscopy | 1 | 2020 | 332 | 0.150 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2012 | 376 | 0.150 |
Why?
|
| Neoadjuvant Therapy | 1 | 2019 | 318 | 0.150 |
Why?
|
| Blood Vessels | 1 | 2017 | 94 | 0.150 |
Why?
|
| Combined Modality Therapy | 2 | 2020 | 1686 | 0.150 |
Why?
|
| RNA Helicases | 1 | 1997 | 35 | 0.150 |
Why?
|
| Lymphocyte Count | 1 | 2017 | 94 | 0.150 |
Why?
|
| Genes, p53 | 2 | 2011 | 109 | 0.150 |
Why?
|
| Gene Rearrangement, beta-Chain T-Cell Antigen Receptor | 2 | 1993 | 17 | 0.140 |
Why?
|
| Cell Movement | 1 | 2020 | 758 | 0.140 |
Why?
|
| Mucin-1 | 1 | 2016 | 44 | 0.140 |
Why?
|
| Cell Hypoxia | 1 | 2017 | 164 | 0.140 |
Why?
|
| Prostatic Neoplasms | 1 | 2008 | 1721 | 0.140 |
Why?
|
| Shock, Septic | 2 | 1988 | 102 | 0.140 |
Why?
|
| Cell Membrane | 1 | 2019 | 666 | 0.140 |
Why?
|
| Clone Cells | 4 | 2006 | 213 | 0.140 |
Why?
|
| Collagen Type I | 1 | 2016 | 62 | 0.140 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 3 | 1990 | 95 | 0.140 |
Why?
|
| Protein Kinases | 1 | 1997 | 209 | 0.140 |
Why?
|
| Homeodomain Proteins | 2 | 2013 | 536 | 0.140 |
Why?
|
| T-Cell Antigen Receptor Specificity | 1 | 2015 | 8 | 0.130 |
Why?
|
| Ischemia | 1 | 2017 | 243 | 0.130 |
Why?
|
| Protein Binding | 3 | 2015 | 1456 | 0.130 |
Why?
|
| In Vitro Techniques | 4 | 2010 | 989 | 0.130 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2017 | 185 | 0.120 |
Why?
|
| Immunization, Passive | 2 | 1993 | 71 | 0.120 |
Why?
|
| Skin Window Technique | 1 | 2013 | 3 | 0.120 |
Why?
|
| Skin Transplantation | 2 | 1997 | 172 | 0.120 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 1993 | 19 | 0.120 |
Why?
|
| Th1 Cells | 1 | 1995 | 164 | 0.120 |
Why?
|
| Genetic Therapy | 1 | 2015 | 342 | 0.120 |
Why?
|
| Growth Disorders | 1 | 1993 | 63 | 0.120 |
Why?
|
| Bacterial Vaccines | 1 | 2013 | 41 | 0.120 |
Why?
|
| Transduction, Genetic | 2 | 2012 | 153 | 0.120 |
Why?
|
| Adenocarcinoma | 3 | 2016 | 1169 | 0.110 |
Why?
|
| Interleukin-15 Receptor alpha Subunit | 1 | 2012 | 6 | 0.110 |
Why?
|
| Actins | 1 | 2016 | 451 | 0.110 |
Why?
|
| RNA, Messenger | 4 | 2004 | 1981 | 0.110 |
Why?
|
| Neovascularization, Pathologic | 2 | 2013 | 353 | 0.110 |
Why?
|
| Cell Survival | 2 | 2012 | 969 | 0.110 |
Why?
|
| Cell Division | 5 | 2003 | 696 | 0.110 |
Why?
|
| Adaptive Immunity | 1 | 2013 | 164 | 0.110 |
Why?
|
| Immunity, Innate | 2 | 2013 | 409 | 0.110 |
Why?
|
| Inclusion Bodies | 1 | 2012 | 34 | 0.110 |
Why?
|
| Retroviridae | 1 | 2012 | 79 | 0.100 |
Why?
|
| Protein Engineering | 1 | 2012 | 140 | 0.100 |
Why?
|
| Interleukin-12 | 2 | 2004 | 108 | 0.100 |
Why?
|
| Treatment Outcome | 2 | 2015 | 7993 | 0.100 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2011 | 141 | 0.100 |
Why?
|
| Antibody Affinity | 2 | 2010 | 38 | 0.100 |
Why?
|
| CD8 Antigens | 5 | 1993 | 82 | 0.090 |
Why?
|
| Endopeptidases | 1 | 2010 | 116 | 0.090 |
Why?
|
| Ribonucleoproteins | 1 | 2010 | 38 | 0.090 |
Why?
|
| Recurrence | 1 | 2013 | 1139 | 0.090 |
Why?
|
| Peritoneal Neoplasms | 2 | 2006 | 177 | 0.090 |
Why?
|
| Perforin | 2 | 2013 | 55 | 0.090 |
Why?
|
| Hemorrhage | 2 | 1988 | 268 | 0.090 |
Why?
|
| Peritoneum | 3 | 2006 | 57 | 0.090 |
Why?
|
| Immunohistochemistry | 2 | 2012 | 1753 | 0.090 |
Why?
|
| Complement C5 | 1 | 1988 | 14 | 0.090 |
Why?
|
| Peptides, Cyclic | 1 | 2009 | 43 | 0.080 |
Why?
|
| Lymph Nodes | 3 | 2003 | 533 | 0.080 |
Why?
|
| Drug Design | 1 | 2009 | 124 | 0.080 |
Why?
|
| Fas Ligand Protein | 2 | 2006 | 49 | 0.080 |
Why?
|
| Mice, SCID | 3 | 1999 | 252 | 0.080 |
Why?
|
| Carcinoma | 1 | 1992 | 436 | 0.080 |
Why?
|
| Shock, Hemorrhagic | 1 | 1988 | 11 | 0.080 |
Why?
|
| Alleles | 2 | 2002 | 1128 | 0.080 |
Why?
|
| Endotoxins | 1 | 1988 | 36 | 0.080 |
Why?
|
| Phagocytosis | 1 | 2008 | 85 | 0.080 |
Why?
|
| Sequence Homology, Amino Acid | 2 | 2001 | 416 | 0.080 |
Why?
|
| Protein Conformation | 3 | 2020 | 881 | 0.070 |
Why?
|
| Bacterial Infections | 1 | 1988 | 182 | 0.070 |
Why?
|
| Macrophage Activation | 1 | 1987 | 46 | 0.070 |
Why?
|
| Acetylgalactosamine | 1 | 2006 | 8 | 0.070 |
Why?
|
| B7-1 Antigen | 1 | 2007 | 75 | 0.070 |
Why?
|
| Galactosyltransferases | 1 | 2006 | 40 | 0.070 |
Why?
|
| Breast Neoplasms | 1 | 2020 | 2903 | 0.070 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2007 | 124 | 0.070 |
Why?
|
| Immunity, Active | 1 | 2006 | 9 | 0.070 |
Why?
|
| Integrases | 1 | 2006 | 59 | 0.070 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2006 | 104 | 0.070 |
Why?
|
| CD40 Antigens | 1 | 2006 | 43 | 0.070 |
Why?
|
| Homeostasis | 1 | 2008 | 409 | 0.070 |
Why?
|
| Male | 11 | 2019 | 40965 | 0.070 |
Why?
|
| Antigen-Antibody Reactions | 1 | 2005 | 23 | 0.070 |
Why?
|
| Deoxycytidine | 1 | 2007 | 237 | 0.070 |
Why?
|
| Lipopolysaccharides | 1 | 1987 | 286 | 0.070 |
Why?
|
| Models, Molecular | 3 | 2020 | 1286 | 0.070 |
Why?
|
| Pancreatic Neoplasms | 4 | 1994 | 645 | 0.070 |
Why?
|
| DNA, Complementary | 2 | 1997 | 393 | 0.070 |
Why?
|
| Peritoneal Cavity | 2 | 1995 | 21 | 0.070 |
Why?
|
| Oligodeoxyribonucleotides | 3 | 1993 | 126 | 0.060 |
Why?
|
| Specific Pathogen-Free Organisms | 2 | 1996 | 74 | 0.060 |
Why?
|
| Genetic Engineering | 2 | 2016 | 114 | 0.060 |
Why?
|
| Antibodies | 3 | 2020 | 350 | 0.060 |
Why?
|
| Interferon Regulatory Factor-1 | 1 | 2004 | 19 | 0.060 |
Why?
|
| Interleukin-18 | 1 | 2004 | 26 | 0.060 |
Why?
|
| Lymphopenia | 1 | 2004 | 28 | 0.060 |
Why?
|
| Estrogen Antagonists | 1 | 2004 | 48 | 0.060 |
Why?
|
| Pore Forming Cytotoxic Proteins | 1 | 2004 | 54 | 0.060 |
Why?
|
| STAT1 Transcription Factor | 1 | 2004 | 52 | 0.060 |
Why?
|
| Transplantation Chimera | 1 | 2004 | 80 | 0.060 |
Why?
|
| Osteosarcoma | 1 | 2004 | 158 | 0.060 |
Why?
|
| Lung Neoplasms | 2 | 2007 | 2262 | 0.060 |
Why?
|
| Brain Neoplasms | 1 | 2009 | 763 | 0.060 |
Why?
|
| Immunoglobulin Switch Region | 1 | 2003 | 10 | 0.060 |
Why?
|
| Hypersensitivity, Delayed | 1 | 2003 | 25 | 0.060 |
Why?
|
| Gene Silencing | 1 | 2004 | 172 | 0.060 |
Why?
|
| Apoptosis | 1 | 2010 | 1683 | 0.060 |
Why?
|
| Stomach Neoplasms | 2 | 1998 | 266 | 0.060 |
Why?
|
| Immune Sera | 1 | 2003 | 52 | 0.060 |
Why?
|
| Lymphoid Tissue | 1 | 2003 | 57 | 0.060 |
Why?
|
| Bone Marrow Transplantation | 1 | 2004 | 286 | 0.060 |
Why?
|
| Methylcholanthrene | 2 | 1996 | 10 | 0.060 |
Why?
|
| Vaccines, DNA | 1 | 2002 | 16 | 0.060 |
Why?
|
| Time Factors | 4 | 2001 | 5210 | 0.060 |
Why?
|
| HLA-A Antigens | 1 | 2002 | 44 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2003 | 79 | 0.060 |
Why?
|
| Luminescent Proteins | 1 | 2003 | 144 | 0.050 |
Why?
|
| Proteins | 2 | 2009 | 777 | 0.050 |
Why?
|
| Adenovirus E1A Proteins | 1 | 2001 | 7 | 0.050 |
Why?
|
| RNA, Neoplasm | 1 | 2001 | 87 | 0.050 |
Why?
|
| Genetic Variation | 2 | 2001 | 1351 | 0.050 |
Why?
|
| Chromium Radioisotopes | 1 | 2001 | 3 | 0.050 |
Why?
|
| Human papillomavirus 16 | 1 | 2020 | 38 | 0.050 |
Why?
|
| Major Histocompatibility Complex | 2 | 1991 | 81 | 0.050 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2001 | 348 | 0.050 |
Why?
|
| DNA Primers | 1 | 2001 | 543 | 0.050 |
Why?
|
| Directed Molecular Evolution | 1 | 2020 | 20 | 0.050 |
Why?
|
| Papillomaviridae | 1 | 2001 | 153 | 0.050 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2020 | 128 | 0.050 |
Why?
|
| Cells, Cultured | 3 | 2005 | 2818 | 0.040 |
Why?
|
| Antineoplastic Agents | 2 | 2012 | 2360 | 0.040 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2020 | 154 | 0.040 |
Why?
|
| Cell Lineage | 1 | 2001 | 273 | 0.040 |
Why?
|
| Cluster Analysis | 1 | 2020 | 369 | 0.040 |
Why?
|
| Antibody Formation | 2 | 2004 | 171 | 0.040 |
Why?
|
| Carcinogenesis | 1 | 2020 | 195 | 0.040 |
Why?
|
| Drug Synergism | 3 | 1988 | 303 | 0.040 |
Why?
|
| Colorectal Neoplasms | 2 | 1998 | 938 | 0.040 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 1991 | 295 | 0.040 |
Why?
|
| Papillomavirus Infections | 1 | 2020 | 239 | 0.040 |
Why?
|
| Mice, Inbred DBA | 1 | 1997 | 148 | 0.040 |
Why?
|
| Intravital Microscopy | 1 | 2017 | 11 | 0.040 |
Why?
|
| Cell Differentiation | 1 | 2003 | 1458 | 0.040 |
Why?
|
| Skin | 2 | 1992 | 554 | 0.040 |
Why?
|
| Blood Cell Count | 1 | 1996 | 79 | 0.040 |
Why?
|
| Whole-Body Irradiation | 1 | 1996 | 63 | 0.040 |
Why?
|
| Histocompatibility Antigen H-2D | 1 | 1996 | 5 | 0.040 |
Why?
|
| DEAD-box RNA Helicases | 1 | 1997 | 62 | 0.040 |
Why?
|
| Jurkat Cells | 1 | 2016 | 77 | 0.040 |
Why?
|
| Substrate Specificity | 1 | 2017 | 347 | 0.040 |
Why?
|
| Lymphocyte Depletion | 3 | 2006 | 97 | 0.040 |
Why?
|
| Tumor Necrosis Factor Ligand Superfamily Member 14 | 2 | 2007 | 14 | 0.030 |
Why?
|
| Carcinoembryonic Antigen | 2 | 1994 | 41 | 0.030 |
Why?
|
| Macrophages, Peritoneal | 1 | 1995 | 21 | 0.030 |
Why?
|
| Ascitic Fluid | 1 | 1995 | 37 | 0.030 |
Why?
|
| Growth Substances | 1 | 1995 | 80 | 0.030 |
Why?
|
| Neoplasm Seeding | 1 | 1994 | 16 | 0.030 |
Why?
|
| Hybridomas | 1 | 1995 | 74 | 0.030 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 1995 | 38 | 0.030 |
Why?
|
| Histidine | 1 | 1995 | 55 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 1995 | 102 | 0.030 |
Why?
|
| Wound Healing | 1 | 2017 | 344 | 0.030 |
Why?
|
| Codon | 1 | 1995 | 124 | 0.030 |
Why?
|
| Endothelial Cells | 1 | 2017 | 428 | 0.030 |
Why?
|
| Interleukin-2 | 1 | 1995 | 249 | 0.030 |
Why?
|
| Sequence Alignment | 1 | 1995 | 351 | 0.030 |
Why?
|
| Killer Cells, Lymphokine-Activated | 1 | 1993 | 27 | 0.030 |
Why?
|
| Injections, Intraperitoneal | 1 | 1993 | 102 | 0.030 |
Why?
|
| Germ-Free Life | 1 | 1993 | 69 | 0.030 |
Why?
|
| Colonic Neoplasms | 3 | 2007 | 556 | 0.030 |
Why?
|
| Ovalbumin | 1 | 2013 | 109 | 0.030 |
Why?
|
| Cell Proliferation | 2 | 2012 | 1578 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 1995 | 526 | 0.030 |
Why?
|
| Microscopy, Electron | 2 | 2009 | 503 | 0.030 |
Why?
|
| Genes, Suppressor | 1 | 1992 | 2 | 0.030 |
Why?
|
| Chimera | 1 | 1992 | 56 | 0.030 |
Why?
|
| Selection, Genetic | 1 | 1996 | 502 | 0.030 |
Why?
|
| Oncogenes | 1 | 1992 | 88 | 0.030 |
Why?
|
| Mammary Tumor Virus, Mouse | 1 | 1992 | 63 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 1993 | 1961 | 0.030 |
Why?
|
| Drug Delivery Systems | 1 | 2012 | 178 | 0.020 |
Why?
|
| Immunocompromised Host | 1 | 1991 | 140 | 0.020 |
Why?
|
| Glycopeptides | 1 | 2010 | 16 | 0.020 |
Why?
|
| Surface Plasmon Resonance | 1 | 2010 | 46 | 0.020 |
Why?
|
| Nuclear Magnetic Resonance, Biomolecular | 1 | 2010 | 60 | 0.020 |
Why?
|
| Static Electricity | 1 | 2010 | 89 | 0.020 |
Why?
|
| Transforming Growth Factors | 1 | 1990 | 12 | 0.020 |
Why?
|
| Antibody Specificity | 1 | 2010 | 129 | 0.020 |
Why?
|
| Transplantation Immunology | 1 | 1990 | 84 | 0.020 |
Why?
|
| Antigen-Antibody Complex | 1 | 2010 | 87 | 0.020 |
Why?
|
| Graft vs Host Disease | 1 | 1992 | 365 | 0.020 |
Why?
|
| Body Weight | 1 | 1991 | 459 | 0.020 |
Why?
|
| Transplantation, Isogeneic | 1 | 1989 | 39 | 0.020 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 2010 | 81 | 0.020 |
Why?
|
| Receptors, Interleukin-2 | 2 | 2005 | 66 | 0.020 |
Why?
|
| Propionibacterium acnes | 1 | 1988 | 6 | 0.020 |
Why?
|
| Circular Dichroism | 1 | 2009 | 117 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 1992 | 937 | 0.020 |
Why?
|
| Secondary Prevention | 1 | 2009 | 162 | 0.020 |
Why?
|
| Crystallography, X-Ray | 1 | 2010 | 485 | 0.020 |
Why?
|
| Facial Neoplasms | 1 | 1988 | 25 | 0.020 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2009 | 318 | 0.020 |
Why?
|
| Neoplasm Staging | 3 | 2005 | 1939 | 0.020 |
Why?
|
| Ligands | 1 | 2009 | 433 | 0.020 |
Why?
|
| Species Specificity | 1 | 1989 | 678 | 0.020 |
Why?
|
| Antigens, Surface | 2 | 2003 | 101 | 0.020 |
Why?
|
| Animal Experimentation | 1 | 2006 | 7 | 0.020 |
Why?
|
| Therapeutic Human Experimentation | 1 | 2006 | 20 | 0.020 |
Why?
|
| Biomarkers, Tumor | 1 | 1994 | 1464 | 0.020 |
Why?
|
| Rats | 1 | 2012 | 3990 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 1989 | 819 | 0.020 |
Why?
|
| Digestive System Neoplasms | 1 | 1984 | 20 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 1987 | 996 | 0.020 |
Why?
|
| Interleukin-10 | 1 | 2005 | 149 | 0.020 |
Why?
|
| Receptors, Tumor Necrosis Factor, Member 14 | 1 | 2004 | 7 | 0.020 |
Why?
|
| Receptors, Virus | 1 | 2004 | 74 | 0.010 |
Why?
|
| Chemokines | 1 | 2004 | 73 | 0.010 |
Why?
|
| Models, Immunological | 1 | 2004 | 80 | 0.010 |
Why?
|
| Middle Aged | 2 | 2020 | 25028 | 0.010 |
Why?
|
| Cell Adhesion Molecules | 1 | 2004 | 163 | 0.010 |
Why?
|
| Encephalitis Virus, Venezuelan Equine | 1 | 2002 | 2 | 0.010 |
Why?
|
| Survival Rate | 2 | 1998 | 1863 | 0.010 |
Why?
|
| Tritium | 1 | 2001 | 133 | 0.010 |
Why?
|
| Clonal Deletion | 1 | 2001 | 23 | 0.010 |
Why?
|
| Diffusion | 1 | 2001 | 93 | 0.010 |
Why?
|
| Injections, Subcutaneous | 1 | 2001 | 117 | 0.010 |
Why?
|
| Viral Vaccines | 1 | 2001 | 43 | 0.010 |
Why?
|
| Organ Specificity | 1 | 2001 | 258 | 0.010 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2003 | 379 | 0.010 |
Why?
|
| Injections, Intralesional | 1 | 1999 | 22 | 0.010 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 1999 | 44 | 0.010 |
Why?
|
| Neoplasm Metastasis | 2 | 1994 | 1056 | 0.010 |
Why?
|
| Dose-Response Relationship, Immunologic | 2 | 1990 | 42 | 0.010 |
Why?
|
| Radioimmunotherapy | 1 | 1999 | 25 | 0.010 |
Why?
|
| Kinetics | 1 | 2001 | 1513 | 0.010 |
Why?
|
| Regression Analysis | 1 | 1999 | 596 | 0.010 |
Why?
|
| Remission Induction | 1 | 1999 | 722 | 0.010 |
Why?
|
| Lung | 1 | 2003 | 1170 | 0.010 |
Why?
|
| Peritoneal Lavage | 1 | 1994 | 10 | 0.010 |
Why?
|
| Bone Marrow Examination | 1 | 1994 | 48 | 0.010 |
Why?
|
| Follow-Up Studies | 2 | 1994 | 3640 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 1994 | 303 | 0.010 |
Why?
|
| RNA-Directed DNA Polymerase | 1 | 1994 | 16 | 0.010 |
Why?
|
| Pancreaticoduodenectomy | 1 | 1994 | 81 | 0.010 |
Why?
|
| Bone Marrow Diseases | 1 | 1994 | 40 | 0.010 |
Why?
|
| Keratins | 1 | 1992 | 63 | 0.010 |
Why?
|
| Lymphocyte Culture Test, Mixed | 1 | 1990 | 74 | 0.010 |
Why?
|
| Prognosis | 1 | 1998 | 3679 | 0.010 |
Why?
|
| Restriction Mapping | 1 | 1990 | 157 | 0.010 |
Why?
|
| Up-Regulation | 1 | 1992 | 712 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 1994 | 1991 | 0.010 |
Why?
|
| Plasmids | 1 | 1990 | 287 | 0.010 |
Why?
|
| Thy-1 Antigens | 1 | 1988 | 16 | 0.010 |
Why?
|
| Exons | 1 | 1990 | 450 | 0.000 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 1990 | 427 | 0.000 |
Why?
|
| Rectal Neoplasms | 1 | 1988 | 116 | 0.000 |
Why?
|
| Aged | 2 | 1994 | 18415 | 0.000 |
Why?
|
| Pancreatitis | 1 | 1984 | 87 | 0.000 |
Why?
|
| Acute Disease | 1 | 1984 | 826 | 0.000 |
Why?
|
| Colitis | 1 | 1984 | 239 | 0.000 |
Why?
|
| Aged, 80 and over | 1 | 1988 | 6509 | 0.000 |
Why?
|
| Adult | 1 | 1988 | 25648 | 0.000 |
Why?
|